FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100073316> ?p ?o ?g. }

• W2100073316 endingPage "127" @default.
• W2100073316 startingPage "119" @default.
• W2100073316 abstract "The objective of this study was to describe a priori protocol-defined analyses to evaluate the safety and tolerability of adjunctive oral lacosamide (200-600 mg/day) in adults (ages 16-70 years) with partial-onset seizures (POS) using data pooled from three similarly designed randomized, double-blind, placebo-controlled trials (SP667, SP754 [NCT00136019], SP755 [NCT00220415]).Patients with POS (≥2 years' duration, ≥2 previous antiepileptic drugs [AEDs]) uncontrolled by a stable dosing regimen of 1-3 concomitant AEDs were randomized to treatment with lacosamide at doses of 200 mg/day, 400 mg/day, or 600 mg/day, or placebo. Studies comprised a 4- to 6-week titration phase to target dose followed by a 12-week maintenance phase. Safety outcomes included treatment-emergent adverse events (TEAEs) of particular relevance to patients with POS, overall TEAEs, and discontinuations due to TEAEs. Post hoc analyses included evaluation of TEAEs potentially related to cognition and TEAEs leading to discontinuation analyzed by concomitant AEDs.One thousand three hundred eight patients were randomized to and received treatment; 944 to lacosamide and 364 to placebo. Most patients (84.4%) were taking 2 or 3 concomitant AEDs. The most common drug-associated TEAEs (reported by ≥5% of patients in any lacosamide dose group and with an incidence at least twice that reported for placebo during the treatment phase) were dizziness (30.6% for lacosamide vs 8.2% for placebo), nausea (11.4% vs 4.4%), and diplopia (10.5% vs 1.9%). Common drug-associated TEAEs generally appeared to be dose-related, and the incidence of each was lower during the 12-week maintenance phase than during the titration phase. Most TEAEs were either mild or moderate in intensity; severe TEAEs were predominantly observed with lacosamide 600 mg/day. No individual serious TEAE occurred in ≥1% of all lacosamide-treated patients. Treatment-emergent adverse events led to discontinuation in 8.1%, 17.2%, and 28.6% of the lacosamide 200-, 400-, and 600-mg/day groups, respectively (vs 4.9% of placebo). Few TEAEs were related to rash, weight loss/gain, changes in clinical chemistry parameters, or psychiatric disturbances, or were seizure-related. The odds of reporting any potential cognition-related TEAE vs placebo increased with dose and were similar between lacosamide doses of 200 and 400mg/day and placebo (odds ratio 1.3, 95% confidence interval 0.7-2.4). Discontinuations due to TEAEs based on most commonly used AEDs taken in combination with lacosamide (all doses combined) were carbamazepine (15.3% [51/334] vs 3.9% [5/129] placebo), lamotrigine (19.2% [56/291] vs 4.3% [5/117]), and levetiracetam (10.1% [28/278] vs 3.9% [4/103]).The safety and tolerability profile of adjunctive lacosamide in this detailed evaluation was similar to that observed in the individual double-blind trials. Adjunctive lacosamide was associated with TEAEs related to the nervous system and gastrointestinal tract, predominantly during titration." @default.
• W2100073316 created "2016-06-24" @default.
• W2100073316 creator A5026329899 @default.
• W2100073316 creator A5032654115 @default.
• W2100073316 creator A5040941933 @default.
• W2100073316 creator A5060176494 @default.
• W2100073316 creator A5075453315 @default.
• W2100073316 creator A5085356343 @default.
• W2100073316 date "2015-11-01" @default.
• W2100073316 modified "2023-10-18" @default.
• W2100073316 title "Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials" @default.
• W2100073316 cites W1596747195 @default.
• W2100073316 cites W180654068 @default.
• W2100073316 cites W1857985470 @default.
• W2100073316 cites W1966601175 @default.
• W2100073316 cites W1970608368 @default.
• W2100073316 cites W1976254460 @default.
• W2100073316 cites W1977688125 @default.
• W2100073316 cites W1978842766 @default.
• W2100073316 cites W1983656228 @default.
• W2100073316 cites W1986346573 @default.
• W2100073316 cites W1990930845 @default.
• W2100073316 cites W1996495192 @default.
• W2100073316 cites W2002555746 @default.
• W2100073316 cites W2009853943 @default.
• W2100073316 cites W2012335416 @default.
• W2100073316 cites W2014853652 @default.
• W2100073316 cites W2017493593 @default.
• W2100073316 cites W2021466585 @default.
• W2100073316 cites W2024857885 @default.
• W2100073316 cites W2035633926 @default.
• W2100073316 cites W2051803500 @default.
• W2100073316 cites W2074658947 @default.
• W2100073316 cites W2084160703 @default.
• W2100073316 cites W2091876851 @default.
• W2100073316 cites W2148655202 @default.
• W2100073316 cites W2148849941 @default.
• W2100073316 cites W2159599047 @default.
• W2100073316 cites W2170352271 @default.
• W2100073316 cites W2750203297 @default.
• W2100073316 cites W3187653885 @default.
• W2100073316 doi "https://doi.org/10.1016/j.yebeh.2015.09.006" @default.
• W2100073316 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26414341" @default.
• W2100073316 hasPublicationYear "2015" @default.
• W2100073316 type Work @default.
• W2100073316 sameAs 2100073316 @default.
• W2100073316 citedByCount "62" @default.
• W2100073316 countsByYear W21000733162015 @default.
• W2100073316 countsByYear W21000733162016 @default.
• W2100073316 countsByYear W21000733162017 @default.
• W2100073316 countsByYear W21000733162018 @default.
• W2100073316 countsByYear W21000733162019 @default.
• W2100073316 countsByYear W21000733162020 @default.
• W2100073316 countsByYear W21000733162021 @default.
• W2100073316 countsByYear W21000733162022 @default.
• W2100073316 countsByYear W21000733162023 @default.
• W2100073316 crossrefType "journal-article" @default.
• W2100073316 hasAuthorship W2100073316A5026329899 @default.
• W2100073316 hasAuthorship W2100073316A5032654115 @default.
• W2100073316 hasAuthorship W2100073316A5040941933 @default.
• W2100073316 hasAuthorship W2100073316A5060176494 @default.
• W2100073316 hasAuthorship W2100073316A5075453315 @default.
• W2100073316 hasAuthorship W2100073316A5085356343 @default.
• W2100073316 hasBestOaLocation W21000733161 @default.
• W2100073316 hasConcept C118552586 @default.
• W2100073316 hasConcept C126322002 @default.
• W2100073316 hasConcept C142724271 @default.
• W2100073316 hasConcept C168563851 @default.
• W2100073316 hasConcept C197934379 @default.
• W2100073316 hasConcept C199475168 @default.
• W2100073316 hasConcept C204787440 @default.
• W2100073316 hasConcept C27081682 @default.
• W2100073316 hasConcept C2778139780 @default.
• W2100073316 hasConcept C2778186239 @default.
• W2100073316 hasConcept C2778375690 @default.
• W2100073316 hasConcept C2778715236 @default.
• W2100073316 hasConcept C2779384505 @default.
• W2100073316 hasConcept C3018162438 @default.
• W2100073316 hasConcept C42219234 @default.
• W2100073316 hasConcept C57658597 @default.
• W2100073316 hasConcept C71924100 @default.
• W2100073316 hasConceptScore W2100073316C118552586 @default.
• W2100073316 hasConceptScore W2100073316C126322002 @default.
• W2100073316 hasConceptScore W2100073316C142724271 @default.
• W2100073316 hasConceptScore W2100073316C168563851 @default.
• W2100073316 hasConceptScore W2100073316C197934379 @default.
• W2100073316 hasConceptScore W2100073316C199475168 @default.
• W2100073316 hasConceptScore W2100073316C204787440 @default.
• W2100073316 hasConceptScore W2100073316C27081682 @default.
• W2100073316 hasConceptScore W2100073316C2778139780 @default.
• W2100073316 hasConceptScore W2100073316C2778186239 @default.
• W2100073316 hasConceptScore W2100073316C2778375690 @default.
• W2100073316 hasConceptScore W2100073316C2778715236 @default.
• W2100073316 hasConceptScore W2100073316C2779384505 @default.
• W2100073316 hasConceptScore W2100073316C3018162438 @default.
• W2100073316 hasConceptScore W2100073316C42219234 @default.
• W2100073316 hasConceptScore W2100073316C57658597 @default.
• W2100073316 hasConceptScore W2100073316C71924100 @default.

• next